Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

alkiviadis.1961 shared this article with you from Inoreader Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure Via The New England Journal of Medicine: Search Results in Endocrinology Sodium–glucose cotransporter 2 (SGLT2) inhibitors represent a major therapeutic advance. They were initially developed to treat hyperglycemia in patients with diabetes mellitus. Subsequently, several SGLT2 inhibitors were shown to lower the risk of hospitalization for heart failure among patients… View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.